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ABSTRACT
Water Soluble Polymerized Metabolic Precursors
Based on PEG-PAMAM-Ac3ManNAz System
for Epigenetic Targeting
Eun Ho Kho
Department of Materials Science and Engineering
College of Engineering
Seoul National University
Over the past several decades, various drug delivery systems have been 
studied to minimize the side effects of anticancer agents and to increase 
delivery efficiency to cancer. Despite the development of numerous
targeting moiedties, several obstacles remain. Tumor heterogeneity and 
quantitative limitation of targeted biomolecules are reasons why 
chemotherapy failed to suppress cancers completely.
In this study, we developed hydrolysable polymerized metabolic 
precursors (pMPs) by conjugating PEG-PAMAM linear dendritic block 
copolymers (LDBC) and triacetylated N-azidoacetyl-mannosamine 
ii
(Ac3ManNAz) via Steglich esterification. As the carboxylic acids of the 
dendron disappear, pMPs became amphiphilic block copolymers and formed 
self assembly of 150 nm in aqueous condition. Regardless of genetic 
phenotypes of tumor cells, pMPs can generate ‘receptor-like’ azide groups 
on the cancer cell surface. Furthermore, the azide groups were visualized by 
ADIBO-Cy5.5 via copper-free click chemistry in vitro condition. It is 
expected that pMPs have synergy with the enhanced premeability and 
retention (EPR) effect and hypersialylation of tumor cells to enable tumor 
cell specific glycan labeling in vivo condition.
Keywords: Tumor Heterogeneity, Metabolic Glycoengineering, Epigenetic 
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1. INTRODUCTION
Metabolic oligosaccharide engineering was pioneered by Reutter and co-
workers to modify the acyl side chains on cell surface sialic acids in living
cells using unnatural sugars as the metabolic precursors1-2. After that 
Carolyn Bertozzi’s group reported bioorthogonal functional groups could 
incroporated into cell membrane sialic acid treating with N-
acetylmannosamine derivatives3-4. Once the unnatural functional group is 
integrated into sialic acid, it is treated with a probe molecule bearing 
complementary bioorthogonal fuctionality for precise glycan imaging5. As 
of now, many groups employed this technique for studying various purposes 
like glycoproteomics, embryogenesis6-7.
As research on drug delivery systems continues, lots of targeting moieties 
have been developed that can target only tumors8-10. Despite the numerous 
targeting moieties developed, tumor heterogeneity is one of the reasons why 
chemotherapy failed to completely suppress cancer11. Recent studies 
reported extensive diversity of genetic phenotype both between and within 
tumors12-13. For this reason, conventional active targeting method using 
specific biomolecule could not deliver therapeutic agent to the entire cancer. 
In addition, the limited number of biological receptors on tumor cells is an 
obstacle to increasing delivery efficiency14. 
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To overcome these limitations, we employed a strategy to artificially 
introduce target receptors into tumor cells. When cancer cells ingest azido 
sugar as a metabolite, the azide group is expressed on the cell surface 
regardless of the genetic phenotype of the cells (Fiugre 1a). Furthermore 
tumor cells showed increased expression of sialic acid sugars on the surface. 
Owing to their high expression of sialic acids, this approach could improve
efficacy15. In order to selectively express azide groups in cancer cells, it is 
important to transport metabolites intensively to cancer tissues.
In our previous study, we developed polymerized metabolic precursors
(pMPs) by conjugating triacetylated N-azideoacetyl-mannosamine
(Ac3ManNAz) and generation 4 poly(amido- amine) (PAMAM [G4.0]). 
However, this materials have some drawbacks about water solubility and 
targeting ability. Herein, we chose PEG-PAMAM linear dendritic block 
copolymer(LDBC) to overcome the defects. We easily synthesized PEG-
PAMAM LDBC using mPEG-NH2 as a core initiator. Since the properties of 
mPEG-PAMAM are mainly determined by PEG, the purification required 
for the synthesis of PEG-PAMAM was carried out by simple precipitation 
method. Polymerized metabolic precursor(pMPs) were synthesized by 
conjugating PEG-PAMAM and triacetylated N-azidoacetyl-
mannosamine(Ac3ManNAz) via Steglich esterification reaction. Since the 
solubility of the dendritic block is determined by its terminal surface, it 
becomes hydrophobic after the coupling with Ac3ManNAz
16. As a result, 
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amphiphilic nature of pMPs led to form self-assembly in aqueous condition.
The size of self-assembly on the aqueous condition was characterized to be
about 150 nm, which is a suitable size to exhibit the EPR effect (Figure 1b).
The human colon adenocarcinoma cells (HT-29) were treated with pMPs. 
Ester bonds of pMPs were hydrolyzed and release free form Ac3ManNAz. 
Our method generates azide groups on the tumor cell surface and these cells 
including subpopulation of tumor cells. Azide groups on the cell membrane 
is visualized by copper free click reaction with ADIBO-Cy5.5.
４
Figure 1. (a) Schematic illustration of the targeting strategy to overcome 
tumor heterogeneity using metabolic glycoengineering and copper-free click 




Methoxy PEG amine (MW : 2K) (mPEG-NH2) was obtained from Sunbio 
(Gunpo, Korea). Anhydrous methanol, Methyl acrylate, Ethylenediamine 
(EDA), Succinic anhydride, N,N’-Dicyclohexylcarbodiimide (DCC), 4-
(Dimethylamino) pyridine (DMAP) were purchased from Sigma-Aldrich (St. 
Louis, MO, USA). EDA was distilled with calcium hydride before use in the 
experiments. Dichloromethane (MC) wase obtained from Daejung 
Chemicals and Metals Co. (Goryeong, Korea). MC was dried over calcium 
hydride. Triacetylated N-azidoacetyl-D-mannosamine (Ac3ManNAz), 
azadibenzocyclooctyne-Cy5.5 (ADIBO-Cy5.5) were achieved from 
FutureChem (Seoul, Korea). 
2.2 Instruments
1H NMR analysis was performed by Bruker Advance 300 MHz 
spectrometer using CDCl3-d6 or D2O as a solvent at room temperature. 
Molecular weight change due to hydrolysis was measured by gel permeation 
chromatography (GPC) with Shimadzu RID-10A refractometer equipped 
with Styragel HR 3, HR 4, HR 4E columns in series. THF was used as an 
eluent with the flow rate of 1.0 mL/min and PEG standards were used for 
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calibration. Measurement of size was performed by Otsuka ELS-Z (Taipei, 
Taiwan). All cellular images were obtained by a confoal laser microscope 
(Leica TCS SP8) (Wetzlar, Germany) with 405 diode (405 nm) and He-Ne 
(633 nm) lasers.
2.3 Synthetic Procedure for PEG-PAMAM Linear Dendritic 
Block Copolymers
Synthesis of the PEG-PAMAM linear dendritic block copolymers is a two 
step process (1) Michael addition of amine groups and (2) exhaustive 
amidation of the resulting methyl esters with large excess of 
ethylenediamine.
2.3.1 Michael addition of amines
First, 2-neck round bottom flask was charged with methyl acrylate (100.0 
equiv of amine). Amine terminated compounds/methanol solution was 
added at room temperature under nitrogen atmosphere. This reaction was 
carried out at 40 oC. Whether the reaction is complete was confirmed by 
using nihydrin test and chloranil test. After the Michael addition reaction 
was finished, the solvent and excess methyl acrylate was evaporated with a 
rotary evaporator. The white sticky residue was precipitated in cold diethyl
７
ether to remove residual impurities and filtered off to give the product, a 
white solid. The solid product was dried under vaccum.
2.3.2 Exhaustive amidation of methyl esters
Ester terminated coumound was dissolved in anhydrous methanol and 
added to ethylenediamine (200.0 equiv of ester) slowly at room temperature 
under nitrogen atmosphere. The reaction is carried out at 45 oC. After 4 days, 
methanol and ethylenediamine were removed under vacuum. The crude 
product was precipitated in cold diethyl ether and filtered off to give a 
product. The product was a white solid and was dried over vacuum.
2.3.3 Synthesis of PEG-PAMAM [G0.5] Dendron
mPEG-PAMAM [G0.5] was synthesized using the procedure described in 
section 2.3.1., starting from mPEG-amine (1.00 g, 0.5 mmol) and methyl 
acrylate (8.61 g, 100.00 mmol) in 5.0 mL anhydrous methanol. The mixture 
was purified by precipitation in cold ether to give white solid (1.02 g, 
93.9 %).
1H NMR in CDCl3-d6 : δPEG(CH3O) = 3.3684 (s) ; δPEG(CH2CH2O) =
3.6327 (m) ; δPAMAM(-COOCH3) = 3.6552 (s) δPAMAM (-CH2COOCH3) = 
2.4396 (t) ; δPAMAM (protons next to tertiary amines) = 2.6 - 2.8 (m)
８
2.3.4 Synthesis of PEG-PAMAM [G1.0] Dendron
mPEG-PAMAM [1.0] was synthesized using the procedure described in 
section 2.3.2., starting from mPEG-G0.5 (0.92 g, 0.42 mmol) and 
ethylenediamine (10.18 g, 169.41 mmol) in 5.0 mL anhydrous methanol. 
The mixture was purified by precipitation in cold ether to give white solid 
(0.85 g, 88.0 %).
1H NMR in CDCl3-d6 : δPEG(CH3O) = 3.3766 (m) ; δPEG(CH2CH2O) =
3.6403 (m) ; δPAMAM (-CH2CONH) = 2.3824 (t) ; δPAMAM (-CONHCH2) =
3.3042 (q) ; δPAMAM (protons next to primary and tertiary amines) = 2.64 -
2.84 (m)
2.3.5 Synthesis of PEG-PAMAM [G1.5] Dendron
mPEG-PAMAM [G1.5] was synthesized using the procedure described in 
section 2.3.1., starting from mPEG-G1.0 (0.81 g, 0.36 mmol) and methyl 
acrylate (12.52 g, 145.40 mmol) in 4.0 mL anhydrous methanol. The 
concentrate was purified by precipitation in cold ether to give white solid 
(0.86 g, 91.8 %).
1H NMR in CDCl3-d6 : δPEG(CH3O) = 3.3700 (s) ; δPEG(CH2CH2O) =
3.6340 (m) ; δPAMAM(-COOCH3) = 3.679 (s) ; δPAMAM (-CH2CONH) =
2.3593 (t) ; δPAMAM (-CONHCH2) = 3.2616 (q) δPAMAM (-CH2COOCH3) =
2.4227 (t) ; δPAMAM (protons next to tertiary amines) = 2.50 – 2.83 (m)
９
2.3.6 Synthesis of PEG-PAMAM [G2.0] Dendron
mPEG-PAMAM [2.0] was synthesized using the procedure described in 
section 2.3.2., starting from mPEG-G1.5 (0.78 g, 0.30 mmol) and 
ethylenediamine (14.58 g, 242.55 mmol) in 4.5 mL anhydrous methanol. 
The mixture was purified by precipitation in cold ether to give white solid 
(0.68 g, 84.0 %).
1H NMR in CDCl3-d6 : δPEG(CH3O) = 3.3809 (s) ; δPEG(CH2CH2O) =
3.6444 (m) ; δPAMAM (-CH2CONH) = 2.3689 (m) ; δPAMAM (-CONHCH2) = 
3.2677 (m) ; δPAMAM (protons next to tertiary and primary amines) = 2.52 -
3.00 (m)
2.3.7 Synthesis of PEG-PAMAM [G2.5] Dendron
mPEG-PAMAM [G2.5] was synthesized using the procedure described in 
section 2.3.1., starting from mPEG-G2.0 (0.69 g, 0.26 mmol) and methyl 
acrylate (17.69 g, 205.60 mmol) in 8.0 mL anhydrous methanol. The 
concentrate was purified by precipitation in cold ether to give white solid 
(0.75 g, 87.0 %).
1H NMR in CDCl3-d6 : δPEG(CH3O) = 3.3744 (s) ; δPEG(CH2CH2O) =
3.643 (m) ; δPAMAM(-COOCH3) = 3.672 (m) ; δPAMAM (-CH2CONH) = 
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2.375 (t) ; δPAMAM (-CONHCH2) = 3.273 (q) ; δPAMAM (-CH2COOCH3) = 
2.435 (t) ; δPAMAM (protons next to tertiary amines) = 2.51 – 2.81 (m)
2.3.8 Synthesis of PEG-PAMAM [G3.0] Dendron
mPEG-PAMAM [3.0] was synthesized using the procedure described in 
section 2.3.2., starting from mPEG-G2.5 (0.70 g, 0.21 mmol) and 
ethylenediamine (19.95 g, 331.99 mmol) in 5.0 mL anhydrous methanol. 
The mixture was purified by precipitation in cold ether to give white solid 
(0.47 g, 63.0 %).
1H NMR in D2O : δPEG(CH3O) = 3.298 (s) ; δPEG(CH2CH2O) = 3.620 
(m) ; δPAMAM (-CH2CONH) = 2.364 (q) δPAMAM (-CONHCH2) = 3.216 (m) 
δPAMAM (protons next to tertiary and primary amines) = 2.54 – 2.87 (m)
2.3.9 Synthesis of Succinamic Acid Terminated PEG-PAMAM [G3.0]
25 mL round bottom flask was charged with mPEG-G3.0 (0.5 g, 0.14 
mmol) and succinic anhydride (0.13 g, 1.25 mmol) and dissolved in 
anhydrous MC (8.00 ml). The solvent was evaporated by rotary evaporator 
and the concentrate was dissolved in H2O to degrade succinic anhydride. 
H2O is removed under vaccum and precipitated in diethyl ether 3 times to 
remove succinic acid.
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1H NMR in D2O : δPEG(CH3O) = 3.310 (s) ; δPEG(CH2CH2O) = 3.618 
(m) ; δPAMAM (-CH2CONH) = 2.404 (m) ; δPAMAM (-CONHCH2) = 3.296 
(m) δPAMAM (-CONHCH2CH2NHCO-) = 3.235 (m) δPAMAM (-
NHCOCH2CH2COOH) = 3.420 (t) δPAMAM (protons next to tertiary amines) 
= 2.66 – 2.80 (m)
2.4 Conjugation of Ac3ManNAz to PEG-PAMAM [G3.0]
25 mL round bottom flask was charged with succinamic terminated mPE-
G3.0 (55.0 mg, 0.0125 mmol), DCC (46.46 mg, 0.225 mmol), DMAP 
(27.50 mg, 0.225 mmol) and dissolved in anhydrous chloroform(6.00 mL)
at ice bath under nitrogen atmosphere. Add Ac3ManNAz (58.29 mg, 0.150 
mmol) to round bottom flask. Remove DCU by using syringe filter and 
evaporate chloroform. The excess reactants were dialyzed in DMSO for 72 
hours using a cellulose membrane (MWCO 2,000 : Spectrum Laboratories, 
TX, USA). After dialysis, the Ac3ManNAz conjugated PEG-PAMAM 
[G3.0] was obtained by lyophilization.
１２
2.5 Preparation of self assembly
In 10 mL round bottom flask, pMP(10.0 mg) was dissolved in 3 mL 
chloroform. Chloroform was evaporated by roatary evaporator at 55 oC. Add 
1 mL of H2O and stirred at 60 
oC for 30 min. The solution was passed 
through 0.22 um syringe filter. Before DLS analysis, the sample was diluted 
with 2 mL of H2O. Size of self assembly was characterized by DLS.
2.6 In vitro release of Ac3ManNAz
To observe of release of Ac3ManNAz from pMP in vitro, Ac3ManNAz 
(10.0 mg) was dissolved in DPBS(1x) (2.0 ml) solution. The samples were 
sampled at 0, 3, 12, 24 h and dried by lyophilization. Obtained samples were 
dissolved in THF and salt was removed by PVDF syringe filters (0.22 um). 
The samples were analyzed by GPC system.
2.7 Cell culture 
HT-29 (Human colon adenocarcinoma) cells were purchased from ATCC 
(Manassas, VA, USA). Those cell lines were maintained in RPMI1640 
(Welgene, Daegu, Korea) containing 10% fetal bovine serum (FBS; 
Welgene, Daegu, Korea), 100 µg/ml streptomycin, and 100 U/ml penicillin 
(Welgene, Daegu, Korea) in a humidified 5% CO2 atmosphere at 37℃. 
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2.8 Cell viability Assay
HT-29 cells were seeded on 96-well plates (5x103 cells/well) and 
incubated for one day. To measure the cytotoxicity of pMPs, the cells were
treated with pMPs with various concentration of Ac3ManNAz: 1.25, 2.5, 5, 
10, 20 µM. After incubation for two days, the cells were washed twice with 
DPBS (pH 7.4) and 20 uL of MTT in serum-free RPMI1640 media (0.5 
mg/mL) was added to each well. After further incubation for 2 h at 37 ºC,
the media was removed and cells were dissolved in 200 uL of DMSO. Then, 
the absorbance of each well was measured at 572 nm using a microplate 
reader (VERSAmaxTM, Molecular Devices Corp., Sunnyvale, CA).
2.9 Cellular imaging to determine the generated azide groups
U87 and HDF cells were seeded onto 35 mm glass-bottom dishes at a 
density of 2.5 x 105 cells in 2 mL of media with variuos concentration of
pMPs (0, 2.5, 5.0, 10.0, 20.0 µM Ac3ManNAz). After incubation for two
days, the cells were washed twice with DPBS (pH 7.4) and incubated for 1 
hour with ADIBO-Cy5.5 (20 µM, final concentration) (Future Chem, Seoul, 
Korea) in 37 ºC incubator. They were rinsed with DPBS (pH 7.4) and fixed 
with a fixative containing 4 % paraformaldehyde for 10 min at room 
temperature. Then, the cells were washed with DPBS (pH 7.4) again and 
stained with DAPI (Invitrogen, Carlsbad, CA, USA) to label nuclei. All 
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cellular images were obtained by a confocal laser microscope (Leica TCS 
SP8, Leica Microsystems GmbH, Germany) with 405 diode (405 nm) and 
He-Ne (633nm) lasers. 
2.10 Western blot analysis of cells
HT-29 cells were seeded onto 100 x 20 mm cell culture plates at a density 
of 2 x 106 cells per plate in 12 mL of media with Ac4ManNAz (20 µM) or 
pMPs (20 µM Ac3ManNAz). After 2 days of incubation, the cells were 
washed twice with DPBS (pH 7.4) and harvested from the plates using a cell 
scraper. The cells were pelleted by centrifugation at 1500 rpm for 5 min, and 
the cell pellets were re-suspended in 500 µl of lysis buffer (1 % SDS, 100 
mM Tris∙HCl, pH 7.4) containing protease inhibitor cocktail (Complete, 
EDTA-free, Roche, NSW, Australia). They were lysed with a probe-type 
sonifier at 4 ºC. Sonicated lysates were incubated at 4 ºC for 30 min to 
further solubilized proteins, and insoluble debris was removed by 
centrifugation for 10 min at 3,000 x g. Final soluble protein concentrations 
were determined by bicinchoninic acid (BCA) protein assay (Pierce, 
Rockford, IL, USA) to be 5 mg/ml. Then, 20 µl of the lysate was incubated 
with 2 µl of phosphine-PEG3-biotin (5 mM in DPBS) (Pierce, Rockford, IL, 
USA) for 6 hours at 37 ºC. SDS-PAGE loading buffer was added to each 
sample and the samples were heated at 95 ºC, before loading onto 10% SPS-
PAGE gel. Proteins were transferred to Hybond P membrane (Amercham, St. 
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Albans, UK), and the membrane was blocked with 5 % bovine serum 
albumin (BSA) in TBST (50 mM Tris∙HCl, 150 mM NaCl, 0.1 % Tween20, 
pH 7.4) for 2 hours. Then, the membrane was incubated with streptavidin-
HRP (diluted 1:2000 in TBST) (Pierce, Rockford, IL, USA) overnight at 4 
ºC. The membrane was rinsed three times with TBST and developed by 
ECL Western Blotting Substrate (Pierce, Rockford, IL, USA).
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3. RESULTS AND DISCUSSION
3.1 Synthesis and characterization of succinamic acid 
terminated PEG-PAMAM [G3.0]
PEG-PAMAM linear dendritic block copolymers (LDBC) were used as a 
backbone structure of the polymerized metabolic precursors (pMPs). 
Despite the advantages of dendrimers in high suface functionality and 
delivery efficiency, there was a limit to its use due to the synthetic barriers 
such as difficult purification process. By using mPEG-NH2 as a core 
initiator, PEG-PAMAM LDBCs were easily synthesized. Purification is 
accomplished by simple precipitation. 
PEG-PAMAM LDBC were scuccessfully synthesized up to 3rd generation 
via iterative michael addition and amidation reaction. Synthetic schemes of 
PEG-PAMAM LDBC are illustrated in scheme 1. In Michael addition 
reaction, we confirm the all of primary and sceondary amines were 
consumed using the nihydrin and chloranil test. The 100 % conversion in 
the amidation reaction was determined by disappearance of hydrogen peak 
of methyl esters in 1H-NMR spectra. Terminal amine groups of PEG-
PAMAM [G3] were converted to carboxylic acid by reacting succinic 
anhydride and characterized by 1H-NMR and ninhydrin test.
1H-NMR spectra of each compounds are shown in Figure 2.
１７
Scheme 1. Synthetic Scheme of Succinamic Terminated PEG-PAMAM 
[G3] Linear Dendritic Block Copolymers
１８
Figure 2. 1H NMR spectra of (a) mPEG-G.0.5 and (b) mPEG-G1.0 in CDCl3
１９
Figure 2. 1H NMR spectra of (c) mPEG-G.1.5 and (d) mPEG-G2.0 in CDCl3
２０
Figure 2. 1H NMR spectra of (e) mPEG-G.2.5 in CDCl3 and (f) mPEG-G3.0 
in D2O
２１
Figure 2. 1H NMR spectra of (g) mPEG-G3.0-COOH in D2O
２２
3.2 Synthesis and characterization of pMPs
For metabolic labeling of tumor cells, we uses Ac3ManNAz as a 
metabolic building block. Because Ac3ManNAz can easily can easily 
produce unnatural sialic acid, overexpressed in various kind of tumors.
PEG-PAMAM [G3] LDBC and Ac3ManNAz was conjugated by Steglich 
esterification (Scheme 2). The reaction was carried out for 5 days. Crude 
products were dialyzed in DMSO to inhibit hydrolysis of ester bonds for 3 
days. After the reaction, pMPs were analyzed by 1H NMR (Figure 3) and the 
1H NMR spectrum promised that 5.7 Ac3ManNAz was conjugated. Also, 
shift of the peak molecular weight without noticeable shoulders in the trace 
of GPC indicated succesful conjugation of mPEG-G3.0 and Ac3ManNAz 
(Figure 4).
２３
Scheme 2. Synthetic Prodcedure of pMPs.
２４
Figure 3. 1H NMR spectra of (a) Ac3ManNAz and (b) pMPs in D2O
２５
Figure 4. GPC spectra of pMPs and mPEG-G3.0.
２６
3.3 Formation of Self-assembly
By conjugating Ac3ManNaz to PEG-PAMAM, the carboxylic acid at the 
terminal of the dendron disappears and the pMPs become amphiphilic block 
copolymers that can form self assemblies in aqueous condition.
The size of self-assembly was analyzed to be about 150 nm by DLS, 
which is a suitable size to exhibit the EPR effect (Figure 5). Its size was 
measured relatively larger than size of linear block copolymers. This is 
consistent with previous research about self assemble behavior of LDBC17-18.
２７
Figure 5. Size distribution of self-aggregates
２８
3.4 In vitro release of Ac3ManNAz
Only free form of Ac3ManNAz can act as a building block in cell 
metabolism, therefore establishing the release of free Ac3ManNaz is 
important. Since tertiary amines in PAMAM play role as a catalyst, 
degradation rate of ester bonds in pMPs was relatively faster than other ester 
bonds19.
Hydrolysis of the ester bonds leds to a decrease in molecular weight and 
secretion of Ac3ManNAz. These phenomenons were obserbed by GPC 
(Figure 6). Relase of Ac3ManNAz was started from 3 hours, and amount of 
it was gradually increased to 24 hours.
２９
Figure 6. GPC spectra of pMPs on time-dependent hydrolysis
３０
3.5 In vitro studies of pMPs
Purpose of in vitro studies is proving the expression of chemical receptors
on tumor cell surface. Despite treatment with 20 uM of pMPs for 48 hours, 
no cytotoxicity was observed (Figure 7). Generation of azide groups was 
visualized by ADIBO-Cy5.5. Since ADIBO has high reactivity to azide 
groups in physiological condition without any catalysts20, ADIBO is chosen 
as complementary bioorthogonal functional groups. Fluorescence intensity 
was depends on concentration of pMPs, and we decided that 20 uM was the 
optimal concentration for cellular imaging (Figure 8a). Western blot analysis 
using phosphine-PEG-biotin and streptavin-HRP demonstrated the 
generation of azide containing glycoprotein on the tumor cell surfaces after 
treatment of pMPs (Figure 8b). In addition, when the expression of the azide 
groups was visualized with time, it did not expressed until 6 hours and 
reached the peak at 48 hour after pMPs treatment. Time-dependent azide 
group expression was also proved by western blot analysis (Figure 9 a,b).
The tendency of expression of azide groups with time is consitent with in 
vitro release experimental data.
３１
Figure 7. Viability of HT-29 cells treated with pMPs for 48 hours
３２
Figure 8. Azide group generation on cell surface in various concentration of 
pMPs (a) Visualization of azide groups on the surface of HT-29 tumor cells 
(b) Coomassie staining and wetern blot analysis of HT-29 tumor cells 
３３
Figure 9. Time dependent azide group generation on cell surface after pMPs 
treatment (a) Visualization of azide groups on the HT-29 tumor cell surface
(b) Coomassie staining and wetern blot analysis of HT-29 tumor cell
３４
4. CONCLUSION
In this study, we developed polymerized metabolic precursors (pMPs) 
using PEG-PAMAM LDBC and Ac3ManNAz. PEG-PAMAM [G3] was 
used as a backbone structure of the pMPs. By using mPEG-NH2 as a 
starting material, all the purification steps required for the PEG-PAMAM 
synthesis were carried out by the simple precipitation method. PEG-
PAMAM LDBCs were conjugated to Ac3ManNAz via Steglich esterification 
to produce hydrolyzable pMPs. Since the amphiphilic nature of pMPs, it can 
form self aggregates in aqueous condition. The size of self  assembly was 
about 150 nm, applicable size to exhibit the EPR effect. 
In vitro studies showed that pMPs did not show cytotoxicity up to 20 uM
and generation of azide groups on the tumor cell surface was confirmed by 
western blot analysis. Furthermore the ‘receptore-like’ azide groups could 
be labeled with ADIBO-Cy5.5 via copper free click chemistry.
The results from in vitro studies supported succesful preparation of 
pMPs and this strategy based on metabolic glycoengineering and copper 
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화학요법은 항암제를 이용하여 암을 치료하는 것이다. 항암제는
암세포에 작용한다면 약이지만, 정상세포에 작용한다면 독성을
야기한다. 따라서 종양에만 선택적으로 약물을 전달하는 약물
전달 체계가 화학요법에 있어 매우 중요하다. 약물 전달 체계에
대한 다양한 연구가 진행되면서 종양 세포만을 표적으로 할 수
있는 타게팅 모이티들이 많이 개발되었다. 하지만 종양세포의
이질성과 표적화 생체 분자의 양적한계 때문에 화학요법을 통한
암의 완치에 실패하였다. 
이러한 한계점들을 극복하기 위하여, 본 연구에서는 고분자화
대사전구체를 이용하여 암 조직에 인공 표적 수용체를 도입하였다.
PEG-PAMAM 과 Triacetylated-N-azido acetyl-D-
mannosamine(Ac3ManNAz)의 화학적 결합을 통해 수용성
고분자화 대사 전구체를 합성하였으며, 이 물질은 수용액 상에서
150 nm 의 자가 조립체를 형성하였다. 세포 실험을 통하여 암의
표현 형질과 관계 없이 모든 종양 세포가 azide 기를 발현하는
것과 생리 조건에서 azide 기가 무동 클릭 화학을 통해 표적화
될 수 있음을 확인하였다. 본 연구에서 개발된 고분자회 대사
４０
전구체를 생체 실험에 사용할 경우, 자가 조립체의 enhanced 
permeability and retention (EPR) 효과와 종양세포의 시알산
과다 발현을 통해 종양세포에만 특이적으로 azide 기를 도입할
수 있으며, 무동 클릭 화학을 통한 azide 기 표적화를 통해 약물
전달 효율을 증가시킬 수 있을 것으로 기대된다.
주요 어: 종양 이질성, 후성 표적화 전략, 고분자화 대사 전구체, 
당 대사 공학, 무동 클릭 화학, 광학 이미징
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